Fig. 5: Drug sensitivity profile of ALK-positive cancer cell lines and PDCs using focused inhibitor library screening. | npj Precision Oncology

Fig. 5: Drug sensitivity profile of ALK-positive cancer cell lines and PDCs using focused inhibitor library screening.

From: GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer

Fig. 5

Cell viability of ALK-positive cancer cell lines and PDCs treated with each inhibitor with or without 300 nM lorlatinib for 72 h was measured (n = 2). Relative cell viability was calculated from each value divided by the DMSO control.

Back to article page